Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Xeris Biopharma Holdings, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-93.1% vs price
Base Case (Median)
-91.1% vs price
Bull Case (75th pct.)
-77.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.69 | -92.5% | High (40%) |
| EV/EBITDA | $0.94 | -89.7% | Medium (20%) |
| EV/FCF | $5.56 | -39.1% | Medium (20%) |
| Earnings Power Value | $0.44 | -95.2% | Medium (50%) |
Based on 4 out of 7 methods, XERS appears overvalued at the current price of $9.13. The base case fair value of $0.81 implies 91.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.